InsiderTrades

Form 4 for REGN Regeneron Pharmaceuticals

Accepted 2024-01-04 00:00:00 ET · period of report 2024-01-02 · accession 0001968202-24-000027 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2024-01-04 2024-01-03 REGN Bassler Bonnie L Dir S - Sale+OE $914.00 -826 1,382 -37% -$755.0K
D 2024-01-04 2024-01-03 REGN Bassler Bonnie L Dir M - OptEx $380.95 +826 2,208 +60% +$314.7K
D 2024-01-04 2024-01-02 REGN Bassler Bonnie L Dir A - Grant $0.00 +135 1,382 +11% $0
D 2024-01-04 2024-01-03 REGN Bassler Bonnie L Dir M - OptEx $0.00 -826 1,654 -33% $0
D 2024-01-04 2024-01-02 REGN Bassler Bonnie L Dir A - Grant $0.00 +1,607 1,607 New $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-01-03 S D 826 $914.00 1,382 D — —
2 Common Common Stock 2024-01-03 M A 826 $380.95 2,208 D — —
3 Common Common Stock 2024-01-02 A A 135 $0.00 1,382 D — —
4 Derivative Non-Qualified Stock Option (right to buy) 2024-01-03 M D 826 $0.00 1,654 D $380.95 · — to 2028-01-02 826 Common Stock (F3) The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.
5 Derivative Non-Qualified Stock Option (right to buy) 2024-01-02 A A 1,607 $0.00 1,607 D $888.34 · — to 2034-01-02 1,607 Common Stock (F4) On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant.